HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 80.0%

Neg 0% Neu 0% Pos 80%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $75 to $95.